Prediction of prostate-specific antigen recurrence in men with long-term follow-up postprostatectomy using quantitative nuclear morphometry

Cancer Epidemiology Biomarkers and Prevention

Volumn 17, Issue 1, 2008, Pages 102-110

  Veltri, Robert W ^a   Miller, M Craig ^b   Isharwal, Sumit ^a   Marlow, Cameron ^a   Makarov, Danil V ^a   Partin, Alan W ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CHEMICAL ANALYSIS; CLINICAL EVALUATION; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DNA CONTENT; FEULGEN STAINING; GLEASON SCORE; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORPHOMETRICS; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PATHOLOGY; PREDICTION; PRIORITY JOURNAL; PROBABILITY; PROSTATE CANCER; PROSTATECTOMY; QUANTITATIVE NUCLEAR MORPHOMETRY; SENSITIVITY AND SPECIFICITY; TISSUE MICROARRAY;

ADENOCARCINOMA; ADULT; AGED; AREA UNDER CURVE; CELL NUCLEUS; COHORT STUDIES; DISEASE-FREE SURVIVAL; DNA, NEOPLASM; FOLLOW-UP STUDIES; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; ROC CURVE; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 38849111771     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-07-0175     Document Type: Article

References (41)

1. Walsh PC. Anatomic radical prostatectomy: evolution of the surgical technique. J Urol 1998;160:2418-24.
2. Walsh PC, Donker PJ. Impotence following radical prostatectomy: insight into etiology and prevention. J Urol 1982;128:492-7.
3. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281:1591-7.
4. Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 2003;169:517-23.
5. Catalona WJ, Smith DS. 5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol 1994;152:1837-42.
6. Catalona WJ, Smith DS. Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer: intermediate-term results. J Urol 1998;160:2428-34.
7. Ohori M, Goad JR, Wheeler TM, Eastham JA, Thompson TC, Scardino PT. Can radical prostatectomy alter the progression of poorly differentiated prostate cancer? J Urol 1994;152:1843-9.
8. Trapasso JG, deKernion JB, Smith RB, Dorey F. The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol 1994;152:1821-5.
9. Freedland SJ, Presti JC, Jr., Amling CL, et al. Time trends in biochemical recurrence after radical prostatectomy: results of the SEARCH database. Urology 2003;61:736-41.
10. Freedland SJ, Humphreys EB, Mangold LA, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005;294:433-9.
11. Ward JF, Moul JW. Rising prostate-specific antigen after primary prostate cancer therapy. Nat Clin Pract 2005;2:174-82.
12. Veltri RW. Molecular biology of serum biomarkers of prostate cancer. In: Kirby RS, Partin AW, Feneley MR, Parsons JK, editors. Prostate cancer: Principles and Practice. London & New York: Taylor & Francis; 2006. p. 269-84.
13. Tricoli JV, Schoenfeldt M, Conley BA. Detection of prostate cancer and predicting progression: current and future diagnostic markers. Clin Cancer Res 2004;10:3943-53.
14. Bacus JW, Grace LJ. Optical microscope system for standardized cell measurements and analyses. Appl Opt 1987;26:3280-93.
15. Veltri RW, Partin AW, Miller MC. Quantitative nuclear grade (QNG): a new image analysis-based biomarker of clinically relevant nuclear structure alterations. J Cell Biochem 2000;Suppl 35:151-7.
16. Veltri RW, Partin AW, Epstein JE, et al. Quantitative nuclear morphometry, Markovian texture descriptors, and DNA content captured on a CAS-200 Image analysis system, combined with PCNA and HER-2/neu immunohistochemistry for prediction of prostate cancer progression. J Cell Biochem 1994;19:249-58.
17. Cairns P, Sidransky D. Molecular methods for the diagnosis of cancer. Biochim Biophys Acta 1999;1423:C11-8.
18. Stein GS, Montecino M, van Wijnen AJ, Stein JL, Lian JB. Nuclear structure-gene expression interrelationships: implications for aberrant gene expression in cancer. Cancer Res 2000;60:2067-76.
19. Veltri RW, Partin AW, Miller CM. Quantitative nuclear grade (QNG): the clinical applications of the quantitative measurement of nuclear structure using image analysis. In: Kelloff GJ, Hawk ET, Sigman CC, editors. Cancer chemoprevention. Totowa (NJ): Humana Press; 2005. p. 97-108.
20. Melamed J, Datta MW, Becich MJ, et al. The cooperative prostate cancer tissue resource: a specimen and data resource for cancer researchers. Clin Cancer Res 2004;10:4614-21.
21. Berman JJ, Datta M, Kajdacsy-Balla A, et al. The tissue microarray data exchange specification: implementation by the Cooperative Prostate Cancer Tissue Resource. BMC Bioinformatics 2004;5:19.
22. Patel AA, Kajdacsy-Balla A, Berman JJ, et al. The development of common data elements for a multi-institute prostate cancer tissue bank: the Cooperative Prostate Cancer Tissue Resource (CPCTR) experience. BMC Cancer 2005;5:108.
23. Liao Z, Datta MW. A simple computer program for calculating PSA recurrence in prostate cancer patients. BMC Urol 2004;4:8.
24. Partin AW, Pound CR, Clemens JQ, Epstein JI, Walsh PC. Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years. Urol Clin North Am 1993;20:713-25.
25. Chodak GW, Neumann J, Blix G, Sutton H, Farah R. Effect of external beam radiation therapy on serum prostate-specific antigen. Urology 1990;35:288-94.
26. Cadeddu JA, Pearson JD, Partin AW, Epstein JI, Carter HB. Relationship between changes in prostate-specific antigen and prognosis of prostate cancer. Urology 1993;42:383-9.
27. Khan MA, Partin AW, Mangold LA, Epstein JI, Walsh PC. Probability of biochemical recurrence by analysis of pathologic stage, Gleason score, and margin status for localized prostate cancer. Urology 2003;62:866-71.
28. Kattan MW, Eastham JA, Stapleton AM,Wheeler TM, Scardino PT. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998;90:766-71.
29. Stephenson AJ, Scardino PT, Eastham JA, et al. Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol 2005;23:7005-12.
30. Cooperberg MR, Pasta DJ, Elkin EP, et al. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol 2005;173:1938-42.
31. Freedland SJ, Mangold LA, Walsh PC, Partin AW. The prostatic specific antigen era is alive and well: prostatic specific antigen and biochemical progression following radical prostatectomy. J Urol 2005;174:1276-81; discussion 81; author reply 81.
32. D'Amico AV, Chen MH, Roehl KA, Catalona WJ. Identifying patients at risk for significant versus clinically insignificant postoperative prostate-specific antigen failure. J Clin Oncol 2005;23:4975-9.
33. Cordon-Cardo C, Kotsianti A, Verbel DA, et al. Improved prediction of prostate cancer recurrence through systems pathology. J Clin Invest 2007;117:1876-83.
34. Noguchi M, Stamey TA, McNeal JE, Yemoto CM. Preoperative serum prostate specific antigen does not reflect biochemical failure rates after radical prostatectomy in men with large volume cancers. J Urol 2000;164:1596-600.
35. Stamey TA. Preoperative serum prostate-specific antigen (PSA) below 10 microg/l predicts neither the presence of prostate cancer nor the rate of postoperative PSA failure. Clin Chem 2001;47:631-4.
36. Stamey TA, Yemoto CM, McNeal JE, Sigal BM, Johnstone IM. Prostate cancer is highly predictable: a prognostic equation based on all morphological variables in radical prostatectomy specimens. J Urol 2000;163:1155-60.
37. Kattan MW. Judging new markers by their ability to improve predictive accuracy. J Natl Cancer Inst 2003;95:634-5.
38. Kattan MW. Evaluating a new marker's predictive contribution. Clin Cancer Res 2004;10:822-4.
39. Debes JD, Sebo TJ, Heemers HV, et al. p300 modulates nuclear morphology in prostate cancer. Cancer Res 2005;65:708-12.
40. Seligson DB, Horvath S, Shi T, et al. Global histone modification patterns predict risk of prostate cancer recurrence. Nature 2005;435:1262-6.
41. Marlow C, Makarov DV, Miller MC, Partin AW, Veltri RW. Improved prediction of PSA biochemical recurrence by quantitative nuclear grade (QNG) using the NCI CPCTR-prostate tissue microarray. AACR Meeting Abstracts, April 2006;47:1242.